ZymoGenetics Begins Trial to Evaluate Cancer Combination Therapy
Posted on: Tuesday, 17 October 2006, 12:01 CDT
ZymoGenetics has reported the start of a phase I/II clinical study of Interleukin 21 in combination with Nexavar in patients with advanced renal cell cancer.
The study will evaluate the safety and preliminary anti-tumor activity of Interleukin 21 (IL-21) in combination with Nexavar.
"Our preclinical data have demonstrated that IL-21 can be additive, or even synergistic, when used in combination with Nexavar and other tyrosine kinase inhibitors," said Nicole Onetto, senior vice president and Chief Medical Officer of ZymoGenetics.
The phase I part of the study will establish the maximum tolerated dose of IL-21 given for one treatment course, consisting of two 5-day cycles of IL-21 in combination with a standard dose of Nexavar administered over a 6-week period. The phase II part of the study will evaluate the safety and preliminary anti-tumor activity of IL-21 at the dose established in phase I in combination with Nexavar.
Because tyrosine kinase inhibitors such as Nexavar inhibit the growth of tumor cells, and IL-21 activates the immune system to target killing of tumor cells, the two therapies may provide additive or synergistic effects.
Source: Datamonitor
Related Articles
- Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
- Infinity Initiates Phase I Study of Tumor Drug
- Semafore Pharmaceuticals Reports Positive Interim Results From a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients With Advanced Solid Tumors
- Semafore and Multiple Myeloma Research Consortium (MMRC) Dose First Patient in Phase I Study of Targeted PI3 Kinase (PI3K) Inhibitor
- ViroPharma and Wyeth Initiate Dosing in Phase 2 Study of HCV-796 in Treatment Naive Patients and Non-Responders
- Cell Therapeutics' Xyotax Shrinks Tumors in Phase I Study
- Xanthus Initiates a Phase 2 Study Of Xanafide in Combination With Ara-C for Treatment Of Secondary AML
- Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Elderly Patients With Primary Sleep Maintenance Insomnia
- Somaxon Pharmaceuticals Announces Positive Results in a Phase II Dose-Finding Study of Low-Dose Doxepin in Adults With Primary Sleep Maintenance Insomnia
- Exenatide LAR Data Support Initiation of Phase 2 Multi-Dose Study in 2005
 |
 |
User Comments (0)
RSS Feeds